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Abstract 
The mammalian mitochondrial electron transport chain catalyzes the oxidation of NADH at pH 8.0 and pH 6.5, and the oxidation of 
NADPH at pH 6.5. The pH-dependencies of the rate of steady-state oxidation of NADPH and NADH by Complex I as well as by its 
flavoprotein fraction have been extensively studied by the laboratory of Hatefi. One model to explain these pH-dependent oxidations was 
proposed by Bakker and Albracht (Biochim. Biophys. Acta 850 (1986) 413-422 and 423-428, modified by Van Belzen and Albracht 
(Biochim. Biophys Acta 974 (1989) 311-320), which predicts that Complex I is a heterodimer with protomer B, containing FMN and 
Fe-S clusters 1-4 in stiochiometric amounts, catalyzing NADH oxidation at pH 8, and Protomer A, containing FMN and Fe-S clusters 2, 
4, catalyzing NAD(P)H oxidation at pH 6.5. A pH-dependent transfer of electrons from protomer A Fe-S clusters 2, 4 to protomer B Fe-S 
clusters 2, 4 is an obligate step in the oxidation of NAD(P)H at low pH. Strict interpretation f this model allows for only three types of 
inhibitor: one which inhibits all three oxidase activities (type 1); one which inhibits NADH oxidase, pH 8.0 (type 4) and a third which 
inhibits NAD(P)H oxidase, pH 6.5 (type 5). Another possibility is that there are three separate pathways of oxidation of NAD(P)H, which 
would allow for a total of seven different types of inhibitor, e.g., the three types above plus type 2 inhibiting NADH oxidase pH 8.0 and 
pH 6.5; type 3 inhibiting NADH oxidase pH 8.0, and NADPH oxidase pH 6.5; type 6 inhibiting NADH oxidase pH 6.5; and type 7 
inhibiting NADPH oxidase pH 6.5. Using a series of thirteen inhibitors of Complex I activity and the chemical modification reagent 
ethoxyformic anhydride (EFA), four different inhibitor types were found: seven inhibitors of type 1, four inhibitors of type 2, one 
inhibitor of type 3 and one inhibitor of type 4. Treatment of submitochondrial p rticles (SMP) with EFA abolished NADH-dependent 
reduction of coenzyme Q at both pH 8.0 and 6.5, while inhibiting NADPH-dependent reduction of coenzyme Q at pH 6.5 by only 30%. 
These results do not support he heterodimer model of Complex I electron transport of Bakker and Albracht, but do support hree separate 
electron flow pathways through complex 1 from reduced pyridine nucleotides to coenzyme Q. A new model of electron flow through 
Complex I based on these finding is proposed. 
Keywords: Mitochondrion; NADH oxidase; NADPH oxidase; Electron transport chain 
Abbreviations: SMP, submitochondrial p rticles; DMSO, dimethyl- 
sulfoxide; S13, 3,3'-dimethylthiacarbocyanine iodide;$23, 3,3'-diethyl- 
thiacarbocyanine iodide; $25, 3,3'-diethylthiadicarbocyanine iodide;$33, 
3,3'-dipropylthiacarbocyanine iodide; $43, 3,3'-dibutylthiacarbocyanine 
iodide; $53, 3,3'-dipentylthiacarbocyanine iod d ; $25, 3,3'-diethyl- 
thiadicarbocyanine iodide; HIDC, 1,1',3,3,3',3'-hexamethylindodicarbo- 
cyanine iodide; HITC, 1,1',3,3,3',3'-hexamethylindotricarbocyanine io- 
dide; DiOC2(3), 3,3'-diethyloxacarbocyanine; DiOC5(3), 3,3'-dipenty- 
loxacarbocyanine; DiOC6(3), 3,3'-dihexyloxacarbocyanine; DiOC2(4), 
3,3'-diethyloxadicarbocyanine; DECA, dequalinium chloride; Di-16-ASQ, 
4-(p-dihexadecylaminostryl)-N-methylquinolinium iodide; DBQ, 2,3-di- 
methoxy-5-methyl-6-decyl-l,4-benzoquinone; EFA, ethoxyformic anhy- 
dride. 
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1. Introduction 
The pathway of electron transport from NADH to oxy- 
gen (NADH oxidase (pH 8.0)) has been investigated in 
great detail in both mitochondria and Paracoccus denitrifi- 
cans (see Refs. [1-3] for reviews of the NADH-ubiquinone 
reductase portion of the oxidase activity). Although it has 
been known for some time that mitochondria catalyze an 
NADH (pH 8.0) oxidase and an NAD(P)H oxidase activity 
at pH 6.5, much less is known about this latter oxidase 
activity, although early studies from the laboratory of 
Hatefi [4-7], indicated that the initial steps of NADPH 
oxidation were catalyzed by Complex I and specifically 
the flavoprotein fraction and that this activity involved 
reduction of FMN, iron-sulfur cluster 2 and perhaps iron- 
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sulfur clusters 3 and 4. Kinetic analysis by Bakker and 
Albracht, later reexamined by Van Belzen and Albracht, of 
electron flow through Complex I, led these workers to 
proposed a heterodimeric model of Complex I [8-10] in 
which protomer B contains FMN and Fe-S clusters 1-4 in 
stiochiometric amounts and oxidizes NADH at pH 8.0, but 
cannot react with NADPH. Protomer A contains FMN and 
Fe-S clusters 2, 3 and 4 and catalyzes NAD(P)H oxidation 
at pH 6.5. A pH-dependent electron transfer from protomer 
A to B between Fe-S clusters 2 and 4 of protomer A to 
Fe-S clusters 2 and 4 of protomer B is a necessary step in 
the oxidation of NAD(P)H and reduction of ubiquinone at 
the lower pH. Thus this model of electron flow envisions 
two different routes of electron transport depending upon 
the electron source and/or pH, converging at Fe-S clusters 
4 and 2 of protomer B to allow NAD(P)H oxidase activity 
to occur at pH 6.5 as well as NADH oxidase at pH 8.0. 
While this hypothesis i intriguing, except for the report by 
Glinn et al. [11] that Complex I has two distinct pyridine 
nucleotide binding sites, a low-affinity NADH and rhein 
binding site and a high-affinity NAD(P)H binding site that 
does not bind rhein, there has been little further substanti- 
ating evidence. As pointed out by Walker in a recent 
review [1], the lack of progress in the area of the electron 
transport pathway through Complex I is hampered both by 
the inability to resolve intramolecular electron transfers 
between Fe-S clusters by EPR and by the lack of inhibitors 
which block at specific intermediate sites. 
For the past several years, workers in this laboratory 
have been investigating new inhibitors of NADH- 
ubiquinone reductase activity in bovine heart submito- 
chondrial particles and P. denitrificans membrane vesicles 
[12-15]. We have discovered a number of inhibitory com- 
pounds which appear to act at or near the rotenone-binding 
site of NADH-ubiquinone reductase and at least one ap- 
pears to act at a different site. 
Using these new inhibitors, along with the two classical 
inhibitors, rotenone and piericidin A, erythrosin 5'-iodo- 
acetamide, reported to bind at the ubiquinone binding site 
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Table 1 
Inhibitor types based upon effect on NADH oxidase (pH 8.0), NADH 
oxidase (pH 6.5) and NADPH oxidase (pH 6.5) 
Inhibitor Effect a 
type NADH oxidase NADH oxidase NADPH oxidase 
(pH 8.0) (pH 6.5) (pH 6.5) 
1 + + + 
2 + + - 
3 + - + 
4 + - - 
5 - + + 
6 - + - 
7 - - + 
a A + indicates inhibition, a -  indicates no inhibition (defined as two or 
more successive concentrations yielding < 50% control activity). 
gM S33 
Fig. 1. Effect of $33 on submitochondrial particle NADH oxidase (pH 
8.0) NADH oxidase (pH 6.5) (A), and NADPH oxidase (pH 6.5) (B) 
activity. Assays were performed as described in Materials and methods. 
NADH oxidase assays (pH 8.0 and 6.5) contained 0.05 mg/ml SMP 
protein; NADPH oxidase assays contained 1 mg/ml SMP protein. Key: 
0 ,  NADH (pH 8.0); ©, NADH (pH 6.5); n ,  NADPH (pH 6.5). Control 
specific activities (units/mg protein) NADH (pH 8.0), NADH (pH 6.5) 
and NADPH (pH 6.5) were 1088, 957 and 15, respectively. 
cal modification reagent reported to inhibit NADH-depen- 
dent reduction of coenzyme Q by ethoxyformylating histi- 
dine and tyrosine residues of Complex I [17], we tested the 
Bakker and Albracht model as well as a model which 
allows for separate electron flow pathways for NADH 
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oxidation at pH 8.0, NADH oxidation at pH 6.5 and 
NADPH oxidation at pH 6.5. This latter model would 
allow for a total of seven different inhibitor types shown in 
Table 1. Strict interpretation of the Bakker and Albracht 
model would allow for only three types of inhibitor, i.e., 
types 1, 4 and 5. In the Bakker and Albracht model, type 1 
inhibitors would block electron transport between pro- 
tomer B Fe-S clusters, 4, 2 to coenzyme Q; type 4 
inhibitors would block electron transfer between at Fe-S 
clusters 1 and 3, while type 5 inhibitors would block the 
pH-dependent electron transfer between protomer A Fe-S 
clusters 4, 2 and protomer B Fe-S clusters 4, 2. 
2. Materials and methods 
2.1. Preparations and assays 
SMP were prepared from bovine hearts as described 
previously [18]. NADH oxidase (pH 8.0) activity was 
determined spectrophotometrically t 25°C as described 
previously [12]. NADH oxidase (pH 6.5) activity was 
determined spectrophotometrically t 25 ° C in a 1 ml assay 
system which was identical to the NADH oxidase (pH 8.0) 
system except that the sodium phosphate buffer was pH 
6.5. NADPH oxidase (pH 6.5) activity was determined 
spectrophotometrically t 25°C in a 1 ml assay system 
containing 2 mM KMops (pH 6.5), 150 mM KCI _+ 200 
/~M rhein [11]. In our hands the activity was identical in 
the absence and presence of rhein. With respect to NADPH 
oxidase activity, (a) treatment SMP for 1 h at 37°C with 
trypsin (1 mg/ml) to destroy pyridine dinucleotide trans- 
hydrogenase activity, or (b) inclusion of 1 p~M palmitoyl 
CoA (to inhibit pyridine dinucleotide transhydrogenase 
activity) in the assay system [19] had no effect (1% or less) 
on the measurable NADPH oxidase activity. NAD(P)H- 
ubiquinone reductase activity was determined spectropho- 
tometrically in a 1 ml assay system described above 
containing 125 /zM DBQ, 50 /~M antimycin A and 10 
mM NaN 3. Treatment of SMP with ethoxyformic anhy- 
dride (final concentration 6.9 mM) was as described by 
Vik and Hatefi [17] except hat SMP was used instead of 
Complex I. Following incubation with EFA for 20 rain at 
0 ° C, SMP were pelleted by centrifugation at 200 000 × g 
for 30 min at 4 ° C, then resuspended in 10 mM KMops 
(pH 7.5), containing 250 mM sucrose to a protein concen- 
tration of 10 mg/ml. Assays with inhibitors were per- 
formed by adding buffer, deionized water, reduced pyri- 
dine nucleotide (DBQ, antimycin A, NaN 3 where applica- 
ble), to the cuvet, mixing, then adding the inhibitor, mix- 
ing again and finally adding SMP to start the reaction. To 
ensure that steady-state rates were being measured, the 
enzymatic rate was followed for up to 10 rain. For all 
inhibitors except rotenone, which is a slow binding in- 
hibitor, the steady-state rate was observed as early as 30 s. 
Steady-state rates were obtained with rotenone at about 1 
min and the linear rate was followed for 10 min. In our 
hands, the time to attain linearity was independent of 
enzyme concentration. After each assay, cuvets were rinsed 
twice with deionized water, six times with 95% (w/v) 
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Fig. 2. Ef fect  o f  D iOC2(4)  on submitochondr ia l  particle NADH ox idase 
(pH 8.0) (A), NADH o×idase (pH 6.5) and NADPH o×idase (pH 6.5) (B)  
act ivity.  Assays  were per fo rmed as descr ibed in Mater ia ls  and Methods.  
NADH ox idase assays  (pH 8.0 and 6.5) conta ined 0.05 mg/ml  SMP 
protein; NADPH o×idase assays  contained I mg/ml  SMP protein. Key:  
0 ,  NADH (pH 8.0); Q ,  NADH (pH 6.5); I I ,  NADPH (pH 6.5). Control  
speci f ic  act iv it ies (un i t s / rag  protein) NADH (pH 8.0), NADH (pH 6.5) 
and NADPH (pH 6.5) were  1088, 957 and 15, respect ively.  
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Table 2 
/~s0 of type 1 inbibitors for NADH oxidase (pH 8.0), NADH oxidase (pH 6.5) and NADPH oxidase (pH 6.5) 
189 
Inhibitor 15 0 a 
NADH oxidase (pH 8.0) NADH oxidase (pH 6.5) NADPH oxidase (pH 6.5) 
Rotenone 0.016 (0.32) 0.025 (0.5) 0.03 (0.03) 
Piericidin A 0.014 (0.28) 0.065 (1.3) 0.035 (0.035) 
Erythrosin 5'-iodoacetamide 0.02 (0.4) 20.5 (410) 41.5 (41.5) 
HIDC 0.05 (1.0) 10.3 (206) 11.5 (11.5) 
HITC 1.5 (30) 10.5 (210) 2.0 (2.0) 
$33 10 (200) 4.5 (90) 19 (19) 
$43 10.5 (210) 3.0 (60) 55 (55) 
a/so in /xM; numbers inparentheses are nmol/mg SMP protein. 
assays were performed in triplicate and data presented 
represent the mean _+ S.E. Protein concentration was deter- 
mined by the biuret reaction as described by Jacobs et al. 
[20] using crystalline bovine serum albumin as a standard. 
2.2. Materials 
Piericidin A was a gift from Dr. Simon DeVries, Uni- 
versity of Amsterdam. NADPH, rotenone, HIDC, HITC, 
DECA, Mops, DBQ, antimycin A, trypsin, palmitoyl CoA 
and DMSO were purchased from Sigma. S13, $23, $25, 
$33, $43 and $53 were obtained from Kodak. Di-16-ASQ, 
DiOC2(3), DiOC5(3), DiOC6(3) and DiOC2(4) and ery- 
throsin 5'-iodoacetamide were purchased from Molecular 
Probes. Rhein was obtained from Aldrich. All other chemi- 
cals were of reagent-grade quality. 
All inhibitors, except piericidin A, which was dissolved 
in ethanol, were dissolved in DMSO at concentrations ator 
near 10 mM. DBQ was dissolved in ethanol at a concentra- 
tion of 2.5 mM. Inhibitors could be stored wrapped in 
aluminum foil at -20°C  for 1 week. 
3. Results 
3.1. Titration of SMP NADH oxidase (pH 8.0), NADH 
oxidase (pH 6.5) and NADPH oxidase (pH 6.5) with 
inhibitors 
Inhibitors were chosen after first testing to eliminate the 
possibility that there was a pH effect on the compound, by 
determining the spectra in the UV and visible region of 
each compound in the buffer systems used in the study. 
Any compound which showed dramatic changes (ap- 
pearance or disappearance of absorbance peaks) was elimi- 
nated. The thiacarbocyanine, $25, showed significant spec- 
tral changes and was eliminated from this study (data not 
shown). A total of sixteen inhibitory compounds howed 
no significant spectral changes. Second, inhibitors were 
tested for their ability to inhibit (>  90% inhibition) the 
SMP NADH-dependent reduction of DBQ at pH 8.0. 
Three inhibitors, Di-16-ASQ, S13 and DiOC5(3) were 
eliminated from the study, based on their inability to 
inhibit (<  50% inhibition) DBQ reduction (data not 
shown), leaving thirteen compounds to be tested. These are 
rotenone, piericidin A, HIDC, HITC, DECA, erythrosin 
5'-iodoacetamide, $23, $33, $43, $53, DiOC2(3), 
DiOC2(4) and DiOC6(3). In this laboratory we have 
demonstrated specific inhibition of mitochondrial and P. 
denitrificans NADH-ubiquinone reductase activity by 
DECA [12], HIDC and HITC [13], DIOC2(3), DIOC5(3), 
DIOC6(3) and DIOC2(4) [15], and have described the 
effect of the thiacarbocyanines S13, $23, $33, $43 and 
$53 on mitochondrial NADH-ubiquinone reductase [14]. 
Ahmed and Krishnamoorthy have reported that erythrosin 
5'- iodoacetamide binds to mitochondrial NADH-  
ubiquinone reductase at the ubiquinone binding site [16]. 
Titrations of the three oxidase activities were performed 
over a 50-100-fold range of concentration (except for 
rotenone and piericidin A, where the range was 20-fold) 
and, for the purposes of this work, inhibition is defined as 
two or more successive concentrations of the inhibitory 
compound which yielded more than 50% of control activ- 
ity. 
Seven of the thirteen compounds inhibited all three 
oxidase activities (type 1 inhibitors-see Table 1). These are 
rotenone, piericidin A, erythrosin 5'-iodoacetamide, HIDC, 
HITC, $33 and $43. Data for one of these type 1 in- 
hibitors, $33, are shown in Fig. 1A,B. /50 for each of the 
seven type 1 inhibitors is given in Table 2. We had 
previously reported that neither $33 nor $43 inhibited 
mammalian mitochondrial NADH oxidase activity at pH 
Table 3 
150 of type 2 inhibitors for NADH oxidase (pH 8.0) and NADH oxidase 
(pH 6.5) 
Inhibitor 15o ~ 
NADH oxidase (pH 8.0) NADH oxidase (pH 6.5) 
DiOC2(4) 2.8 (56) 10 (200) 
DiOC6(3) 0.08 (1.6) 17 (340) 
$23 1.2 (24) 48 (960) 
$53 10.2 (204) 2.1 (42) 
a 15 o in /xM; numbers inparentheses are nmol/mg SMP protein. 
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8.0 based upon a titration from 1 to 7/xM [14]. Titrations 
of both of these compounds was stopped at 7 /xM, since 
precipitation was observed in the assay system above this 
concentration. Using the mixing regimen described in 2.1 
above, there was no precipitation, and inhibition of NADH 
oxidase (pH 8.0) was demonstrated with the 150 of both of 
these two thiacarbocyanines being about 10 /xM. With the 
exception of rotenone, $33 and $43, the 150 for NADH 
oxidase (pH 8.0) was lower than that for either NADH or 
NADPH oxidase (pH 6.5). These results are consistent 
with both the Bakker and Albrach heterodimer model and 
the three separate pathways model. 
Four of the thirteen compounds inhibited NADH oxi- 
dase at pH 8.0 and 6.5 but did not inhibit NADPH oxidase 
(pH 6.5) (type 2 inhibitors -see Table 1). These are 
DiOC6(3), DiOC2(4), $23 and $53. Data for DiOC2(4) are 
shown in Fig. 2A,B. /so for each of the four type 2 
inhibitors is given in Table 3. As with $33 and $43, we 
had also previously reported that $53 was not an inhibitor 
of NADH oxidase (pH 8.0) [14], but with the mixing 
regimen in 2.1, we were able to extend the titration range 
to observe inhibition. With the exception of $53, the /so 
for NADH oxidase (pH 8.0) is lower than for NADH 
oxidase (pH 6.5). These results are not consistent with the 
Bakker and Albracht heterodimer model, but are consistent 
with the three separate pathways model. 
"7, 
10 20  30  40  50  60  70  80  90  100  
ttM DECA 
Fig. 3. Effect of DECA on submitochondrial particle NADH oxidase (pH 
8.0), NADH oxidase (pH 6.5) and NADPH oxidase (pH 6.5) activity. 
Assays were performed as described in Materials and methods. NADH 
oxidase assays (pH 8.0 and 6.5) contained 0.05 mg/ml SMP protein; 
NADPH oxidase assays contained 1 mg/ml SMP protein. Key O, 
NADH (pH 8.0); O, NADH (pH 6.5); II, NADPH (pH 6.5). Control 
specific activities (units/mg protein) NADH (pH 8.0), NADH (pH 6.5) 
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Fig. 4. Effect of DiOC2(3) on submitochondrial particle NADH oxidase 
(pH 8.0) (A), NADH oxidase (pH 6.5) and NADPH oxidase (pH 6.5) (B) 
activity. Assays were performed as described in Materials and methods. 
NADH oxidase assays (pH 8.0 and 6.5) contained 0.05 mg/ml SMP 
protein; NADPH oxidase assays contained I mg/ml SMP protein. Key: 
0,  NADH (pH 8.0); O, NADH (pH 6.5); II, NADPH (pH 6.5). Control 
specific activities (units/mg protein) NADH (pH 8.0), NADH (pH 6.5) 
and NADPH (pH 6.5) were 1088, 957 and 15, respectively. 
One of the thirteen compounds, DECA, inhibited NADH 
oxidase (pH 8.0) and NADPH oxidase (pH 6.5), but did 
not inhibit NADH oxidase (pH 6.5) (type 3 inhibitor -see 
Table 1). These results are presented in Fig. 3. The 150 for 
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NADH oxidase (pH 8.0) was 9.5 /zM and it was 28 /xM 
for NADPH oxidase (pH 6.5). The 150 for NADH oxidase 
(pH 8.0) is close to the previously reported 11 /xM for this 
activity [12]. As with the type 2 inhibitors, this inhibition 
pattern by DECA is not consistent with the Bakker and 
Albracht heterodimer model, but is consistent with the 
three separate pathways model. 
One of the thirteen compounds, DiOC2(3) inhibited 
NADH oxidase (pH 8.0), but not NADH or NADPH 
oxidase (pH 6.5) (type 4 inhibitors -see Table 1). These 
results are presented in Fig. 4A,B. The 150 for NADH 
oxidase (pH 8.0) was 7.3 /zM, which closely compares 
with the 9/zM previously reported for this compound [15]. 
These results are consistent with either the Bakker and 
Albracht heterodimer model or the three separate pathways 
model. 
None of the thirteen compounds examined in this study 
inhibited NADH and NADPH oxidase (pH 6.5) only (type 
5 inhibitors -see Table 1), inhibited NADH oxidase (pH 
6.5) only (type 6 inhibitors -see Table 1), or inhibited 
NADPH oxidase (pH 6.5) only (type 7 inhibitors -see 
Table 1). 
3.2. Effect of ethoxyformic anhydride on SMP NADH 
oxidase (pH 8.0), NADH oxidase (pH 6.5) and NADPH 
oxidase (pH 6.5) 
Treatment of SMP with ethoxyformic anhydride [19], as 
described in 2.1, completely abolished NADH-dependent 
reduction of DBQ at pH 8.0 and pH 6.5 (100% inhibition), 
but only resulted in a 30% inhibition of NADPH-depen- 
dent reduction of DBQ at pH 6.5. Taken together, these 
results are not consistent with the Bakker and Albracht 
heterodimer model, since strict interpretation of the model 
would predict hat compounds which inhibited NADH-de- 
pendent reduction of DBQ (pH 6.5) would also inhibit 
NADPH-dependent reduction of DBQ (pH 6.5). The data, 
however, are consistent with the three separate pathways 
model. 
4. Discussion 
The results presented here do not support the het- 
erodimer model of two separate lectron transport path- 
ways through Complex I proposed by Bakker and A1- 
bracht, but are consistent with a three separate pathways 
for the reduction of coenzyme Q by reduced pyridine 
nucleotides. The fact that neither trypsin treatment nor 
inclusion of palmitoyl CoA in the assay system had any 
effect on the NADPH oxidase activity at pH 6.5 indicates 
that these results cannot be explained on the basis of 
pyridine dinucleotide transhydrogenase interference, al- 
though no NAD + was added to the assay systems. Further, 
care was taken that the effects observed in the study were 
not due to the differences in pH by eliminating any 
compound which showed significant changes in visible 
and ultraviolet spectra, which eliminated one compound 
from our study. Except for type 4 inhibitors, the other 
three inhibitor types observed in this study affected activi- 
ties at both pH 8.0 and 6.5, which argues further that the 
effects presented here were not due to pH effects on 
binding of the inhibitory compounds to the Complex I 
portion of the electron transport chain. In the Bakker and 
Albracht model, an inhibitor with acts at pH 6.5 should 
inhibit both NADH and NADPH oxidase at this pH, i.e., 
inhibit by binding at the same site. The fact that four 
compounds were found to inhibit NADH oxidase (pH 6.5) 
but not NADPH oxidase (pH 6.5) (type 2 inhibitors), and 
one compound was found to inhibit NADPH oxidase (pH 
6.5) but not NADH oxidase (pH 6.5) indicates that there 
are different inhibitory binding sites at this pH rather than 
one inhibitor site. The effectiveness of the inhibitor as 
measured by 150 may depend on the steady-state rates of 
the enzyme reaction, which are different for NADH and 
NADPH (see Fig. 1, for specific activities). Whereas the 
ratios of specific activities for NADH oxidase (pH 8.0) to 
NADPH oxidase (pH 6.5) is 72.5, the ratios of 150 values 
for the same two activities (on a nmol /mg SMP protein 
basis) for type 1 inhibitors (see Table 2) vary from 9.6. 
10-3 for erythrosin 5'-iodoacetamide to 15 for HITC, and 
for DECA, a type 3 inhibitor the ratio of the 150 values for 
these same two activities is 6.8. Thus, there is no general 
correlation of the rates of enzymatic reaction with inhibitor 
effectiveness, which argues against the present results 
being a function of differences in enzymatic reaction rates. 
The possibility that the results could be due to redox 
acceptor activity of the compounds tested (or slight impuri- 
ties which might be present in the samples tested) was 
eliminated by excluding any compound which did not 
exhibit more than 90% inhibition of NADH-dependent 
reduction of DBQ at pH 8.0. This test eliminated three 
compounds from the present study. Thus, it is highly 
unlikely that the results presented here can be explained on 
the basis of pH effects on chemical structure of the in- 
hibitor or its binding site. 
Demonstration of four type 2 inhibitor compounds and 
one type 3 inhibitor compound argue that there are indeed 
three separate pathways for the reduction of coenzyme Q 
by reduced pyridine nucleotides through Complex I. These 
two types of inhibitor are inconsistent with the Bakker and 
Albracht model. Further, the fact that chemical modifica- 
tion by ethoxyformic anhydride resulted in complete aboli- 
tion of NADH-dependent reduction of DBQ at pH 8.0 and 
6.5, while only inhibiting NADPH-dependent reduction of 
DBQ at pH 6.5, strengthens the possibility that there are 
three separate pathways for reduction of coenzyme Q by 
reduced pyridine nucleotides. The fact that no type 5, 6 or 
7 inhibitors were identified in the present study does not 
imply that they are nonexistent, but rather that a more 
comprehensive s arch will be necessary. A large number 
of compounds have been found to inhibit Complex I 





~,. FMN.__-S"2S~_~3 ,~, " 
X~4," 
FMN- -~I - -~3 :- 4 ~- 2 -Q  
Protomer B 
Fig. 5. Schematic representation f the modified heterodimer model of 
three separate pathways for oxidation of reduced pyridine nucleotides by 
Complex I. The arrows indicate the proposed pathway of electron flow 
within the enzyme. 
activity and only 13 were examined here. Finding type 7 
inhibitors will require looking for compounds which in- 
hibit NADPH-linked activities, as well as an empirical 
search. 
As a working hypothesis, we propose a modified het- 
erodimer model which could explain the existence of three 
separate pathways and account for the action of the seven 
different inhibitor types. This model is presented in Fig. 5. 
In this model, both protomers A and B would be able to 
reduce coenzyme Q in a pH-dependent manner. Type 1 
inhibitors would block the pH-independent reduction of 
coenzyme Q by reduced Fe-S cluster 2 in either protomer. 
Type 2 inhibitors would inhibit the pH-independent direct 
reduction of Fe-S cluster 2 by reduced Fe-S cluster 3 in 
either protomer, bypassing Fe-S cluster 4 in protomer B. 
Type 3 inhibitors would block the pH-independent reduc- 
tion of Fe-S cluster 2 by reduced Fe-S cluster 4 in either 
protomer. Type 4 inhibitors would block reduction of Fe-S 
cluster 3 by reduced Fe-S cluster 1 in protomer B. Type 5 
inhibitors would block the low pH-dependent reduction of 
Fe-S cluster 2 by either reduced Fe-S clusters 3 or 4 in 
protomer A. Type 6 inhibitors would block the low pH-de- 
pendent direct reduction of Fe-S cluster 2 by Fe-S cluster 3 
in protomer A. Type 7 inhibitors would block the low 
pH-dependent reduction of Fe-S cluster 2 by reduced Fe-S 
cluster 4 in protomer A. We have kept the heterodimer 
portion of the Bakker and Albracht model, since it best 
explains our results and there is no evidence to suggest 
that Complex I is not a heterodimer in mammalian mito- 
chondria. Weiss and co-workers have presented convincing 
evidence [21] that the polypeptide subunits of Neurospora 
crassa mitochondrial Complex I are arranged in an L 
shaped bipartite structure with one arm embedded in the 
membrane and the other arm protruding into the matrix. 
The two arms undergo independent assembly before join- 
ing to form a mature functioning Complex I [22]. How- 
ever, no such structure has yet been observed for mam- 
malian mitochondrial Complex I. 
Researchers have long been puzzled at the complexity 
of mammalian NADH-ubiquinone reductase. No function 
has yet been ascribed for most of the 42 or more subunits 
of this electron transport macromolecular complex [1]. If 
the heterodimer three separate lectron pathways model of 
complex 1 is indeed correct, then perhaps many of the 
subunits function in modulating and/or facilitating elec- 
tron transport along the three separate pathways. Numer- 
ous EPR studies have failed to delineate the exact pathway 
of electron flow from NADH to coenzyme Q at pH 8.0, 
although a some features are fairly well established. 
Molecular biology methods have been helpful in determin- 
ing the primary structure of many of the subunits of 
Complex I [1,23] and perhaps expression systems and 
site-directed mutagenesis will lead to greater insights into 
the complexity of this macromolecule. However, the use of 
specific inhibitors coupled with these other techniques may 
offer the best chance of success in delineating the compli- 
cated patterns of electron flow. Most of the compounds 
used in this study are highly fluorescent; many are laser 
dyes. The clever use of photoaffinity analogs of some of 
these compounds, together with the finding of inhibitors of 
types 5-7, could be useful in putting together the pieces of 
this complicated puzzle of electron flow from reduced 
pyridine nucleotides to coenzyme Q in the mitochondrial 
respiratory chain. 
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